Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026 (The Manila Times) - Sep 22, 2026 - "New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD...Additional analyses will assess glucocorticoid-associated toxicity and vaccine responses."
Clinical data • P3 data • Immunology • Inflammation
|